The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
70 - 90% by HPLC.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions. - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer. - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent. - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised. - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
Matrix metallopeptidase 14 (membrane inserted)
Matrix metalloproteinase 14
Membrane type 1 matrix metalloproteinase
Membrane type 1 metalloprotease
Membrane type matrix metalloproteinase 1
Membrane-type matrix metalloproteinase 1
Membrane-type-1 matrix metalloproteinase
MT MMP 1
Seems to specifically activate progelatinase A. May thus trigger invasion by tumor cells by activating progelatinase A on the tumor cell surface. May be involved in actin cytoskeleton reorganization by cleaving PTK7.
Expressed in stromal cells of colon, breast, and head and neck. Expressed in lung tumors.
Belongs to the peptidase M10A family. Contains 4 hemopexin-like domains.
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
The precursor is cleaved by a furin endopeptidase.
Membrane. Melanosome. Identified by mass spectrometry in melanosome fractions from stage I to stage IV.